Skip to main content
Article thumbnail
Location of Repository

Protection by Anti-β-Glucan Antibodies Is Associated with Restricted β-1,3 Glucan Binding Specificity and Inhibition of Fungal Growth and Adherence

By Antonella Torosantucci, Paola Chiani, Carla Bromuro, Flavia De Bernardis, Angelina S. Palma, Yan Liu, Giuseppina Mignogna, Bruno Maras, Marisa Colone, Annarita Stringaro, Silvia Zamboni, Ten Feizi and Antonio Cassone


Anti-β-glucan antibodies elicited by a laminarin-conjugate vaccine confer cross-protection to mice challenged with major fungal pathogens such as Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans. To gain insights into protective β-glucan epitope(s) and protection mechanisms, we studied two anti-β-glucan monoclonal antibodies (mAb) with identical complementarity-determining regions but different isotypes (mAb 2G8, IgG2b and mAb 1E12, IgM). C. albicans, the most relevant fungal pathogen for humans, was used as a model

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2001). A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
    2. (2006). A drug-sensitive genetic network masks fungi from the immune system.
    3. (2006). A fungicidal monoclonal antibody protects against murine invasive candidiasis.
    4. (2005). A novel glyco-conjugate vaccine against fungal pathogens.
    5. (2006). A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis.
    6. (2006). A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice.
    7. (1973). A technique for ultracryotomy of cell suspensions and tissues.
    8. (1998). A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.
    9. (2007). Advances in combating fungal diseases: Vaccines on the threshold.
    10. (2004). ALS3 and ALS8 represent a single locus that encodes a Candida albicans adhesin; functional comparisons between
    11. (2003). An analysis of the Candida albicans genome database for soluble secreted proteins using computer-based prediction algorithms.
    12. (2007). An antibeta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo.
    13. (2008). An integrated model of the recognition of Candida albicans by the innate immune system.
    14. (2005). Antibodymediated protective immunity in fungal infections.
    15. (2008). Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact.
    16. (1996). Bacic A
    17. (2006). Beta-glucan is a fungal determinant for adhesion-dependent human neutrophil functions.
    18. (2007). Betaglucan of Candida albicans cell wall causes the subversion of human monocyte differentiation into dendritic cells.
    19. (2008). Candida albicans cell wall comprises a branched beta-d-(1R6)-glucan with beta-d-(1R3)-side chains.
    20. (1999). Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis.
    21. (2004). Casadevall A
    22. (2000). Cassone A
    23. (2005). Changing patterns and trends in systemic fungal infections.
    24. (2001). Characterization of agglutinin-like sequence genes from non-albicans Candida and phylogenetic analysis of the ALS family.
    25. (2006). Comparative analysis of cell wall surface glycan expression in Candida albicans and Saccharomyces cerevisiae yeasts by flow cytometry.
    26. (2008). Complementary adhesin function in C. albicans biofilm formation.
    27. (1995). Covalent association of beta-1,3-glucan with beta-1,6-glucosylated mannoproteins in cell walls of Candida albicans.
    28. (2007). Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: Galactomannan, mannan and (1R3)-beta-D-glucan antigens.
    29. (2005). Dectin-1 escape by fungal dimorphism.
    30. (2005). Dectin-1 mediates macrophage recognition of Candida albicans yeast but not filaments.
    31. (2005). Defining criteria for anti-mannan antibodies to protect against candidiasis.
    32. (2008). Discovering the secrets of the Candida albicans agglutinin-like sequence (ALS) gene family–a sticky pursuit.
    33. (2001). DNA array studies demonstrate convergent regulation of virulence factors by
    34. (2008). Dynamic, morphotypespecific Candida albicans beta-glucan exposure during infection and drug treatment.
    35. (2006). Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis.
    36. (2005). Features and functions of covalently linked proteins in fungal cell walls.
    37. (2004). Functional and structural diversity in the als protein family of Candida albicans.
    38. (2005). Functional specificity of Candida albicans Als3p proteins and clade specificity of ALS3 alleles discriminated by the number of copies of the tandem repeat sequence in the central domain.
    39. (2006). Fungal diseases: An evolving public health challenge.
    40. (2008). Fungal vaccines: Real progress from real challenges.
    41. (2008). Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans.
    42. (2005). gene regulation in the fungal pathogen, Candida albicans.
    43. (2005). Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood.
    44. (1996). Human constant regions influence the antibody binding characteristics of mouse-human chimeric IgG subclasses.
    45. (2007). Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis.
    46. (2002). Induced humoral immunity and vaccination against major human fungal pathogens.
    47. (2005). Induction of the Candida albicans filamentous growth program by relief of transcriptional repression: A genome-wide analysis.
    48. (2007). Integrated proteomics and genomics strategies bring new insight into Candida albicans response upon macrophage interaction.
    49. (2002). Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine.
    50. (2006). Invasive fungal infections: A review of epidemiology and management options.
    51. (1998). Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice.
    52. (2006). Ligands for the beta-glucan receptor, dectin-1, assigned using ‘‘designer’’ microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides.
    53. (1995). Llobell A
    54. (1990). Lymphoproliferative and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans.JG e n
    55. (2005). Managing infections in the immunocompromised patient.
    56. (2000). Molecular organization of the alkali-insoluble fraction of Aspergillus fumigatus cell wall.
    57. (2001). Molecular organization of the cell wall of Candida albicans.
    58. (2007). Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.
    59. (2005). Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis. Clin Diagn Lab Immunol 12(9): 1063–1068. Anti-b-Glucan mAbs PLoS
    60. (2007). Neoglycolipid probes prepared via oxime ligation for microarray analysis of oligosaccharide-protein interactions.
    61. (2007). Plaine A
    62. (2001). Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens.
    63. (2003). Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.
    64. (2004). Preventative and therapeutic vaccines for fungal infections: From concept to implementation.
    65. (1988). Production and characterisation of a monoclonal antibody to a cell-surface, glucomannoprotein constituent of Candida albicans and other pathogenic Candida species.
    66. (2004). Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2.
    67. (2005). Protective antifungal yeast killer toxin-like antibodies.
    68. (1996). Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of anti-Candida cell-mediated immune responses in humans.
    69. (2007). Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 51(2): 510–520. Anti-b-Glucan mAbs PLoS
    70. (2004). Recombinant antibodies: A natural partner in combinatorial antifungal therapy.
    71. (1993). Role of heavy chain constant domains in antibody-antigen interaction. apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains.
    72. (2008). Synthetic glycopeptide vaccines combining {beta}-mannan and peptide epitopes induce protection against candidiasis.
    73. (2005). The betaglucan receptor dectin-1 recognizes specific morphologies of Aspergillus fumigatus.
    74. (1996). The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins.
    75. (2000). The cell wall architecture of Candida albicans wild-type cells and cell wall-defective mutants.
    76. (2006). The changing epidemiology of invasive fungal infections: New threats.
    77. (1999). The contribution of cell wall proteins to the organization of the yeast cell wall.
    78. (2008). The hyphal-associated adhesin and invasin Als3 of Candida albicans mediates iron acquisition from host ferritin.
    79. (2005). The immune response to fungal infections.
    80. (2004). The interaction of human dendritic cells with yeast and germ-tube forms of Candida albicans leads to efficient fungal processing, dendritic cell maturation, and acquisition of a Th1 response-promoting function.
    81. (2004). The role of dectin-1 in antifungal immunity.
    82. (2008). Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.
    83. (1997). Torosantucci A

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.